Literature DB >> 19557020

Paradoxical vascular-fibrotic reaction after intravitreal bevacizumab for retinopathy of prematurity.

L C Zepeda-Romero, J A Liera-Garcia, J A Gutiérrez-Padilla, C I Valtierra-Santiago, C D Avila-Gómez, L J Cardenas-Lamas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19557020     DOI： 10.1038/eye.2009.156

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  11 in total

1.  Delayed onset atypical vitreoretinal traction band formation after an intravitreal injection of bevacizumab in stage 3 retinopathy of prematurity.

Authors:  B J Lee; J H Kim; H Heo; Y S Yu
Journal:  Eye (Lond)       Date:  2012-06-15       Impact factor: 3.775

2.  [Pharmacological treatment for retinopathy of prematurity].

Authors:  A Stahl; H Agostini; C Jandeck; W Lagrèze
Journal:  Ophthalmologe       Date:  2011-08       Impact factor: 1.059

3.  Clinical Management of Recurrent Retinopathy of Prematurity after Intravitreal Bevacizumab Monotherapy.

Authors:  Helen A Mintz-Hittner; Megan M Geloneck; Alice Z Chuang
Journal:  Ophthalmology       Date:  2016-05-27       Impact factor: 12.079

4.  Case series of infants presenting with end stage retinopathy of prematurity to two tertiary eye care facilities in Mexico: underlying reasons for late presentation.

Authors:  Luz C Zepeda-Romero; Alonso Meza-Anguiano; Juan C Barrera-de León; Eusebio Angulo-Castellanos; Marco A Ramirez-Ortiz; José A Gutiérrez-Padilla; Clare E Gilbert
Journal:  Matern Child Health J       Date:  2015-06

5.  Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.

Authors:  Helen A Mintz-Hittner; Kathleen A Kennedy; Alice Z Chuang
Journal:  N Engl J Med       Date:  2011-02-17       Impact factor: 91.245

6.  Appropriate dose of intravitreal ranibizumab for ROP: a retrospective study.

Authors:  Yingying Chen; Shaoli Wang; Siying Chen; Xingyue Chen; Lizhen Han; Qionglei Zhong; Kaiyan Zhang
Journal:  BMC Ophthalmol       Date:  2022-06-21       Impact factor: 2.086

7.  [Current therapeutic options in retinopathy of prematurity].

Authors:  T U Krohne; S Aisenbrey; F G Holz
Journal:  Ophthalmologe       Date:  2012-12       Impact factor: 1.059

Review 8.  A Systematic Review and Meta-Analysis on the Safety of Vascular Endothelial Growth Factor (VEGF) Inhibitors for the Treatment of Retinopathy of Prematurity.

Authors:  Laura Pertl; Gernot Steinwender; Christoph Mayer; Silke Hausberger; Eva-Maria Pöschl; Werner Wackernagel; Andreas Wedrich; Yosuf El-Shabrawi; Anton Haas
Journal:  PLoS One       Date:  2015-06-17       Impact factor: 3.240

9.  Asymmetric Outcomes of Type 1 Retinopathy of Prematurity after Bilateral Intravitreal Ranibizumab Treatment.

Authors:  Qiujing Huang; Qi Zhang; Yu Xu; Xunda Ji; Ping Fei; Jie Peng; Yi-An Li; Peiquan Zhao
Journal:  J Ophthalmol       Date:  2017-03-29       Impact factor: 1.909

10.  Effect of Decorin and Bevacizumab on oxygen-induced retinopathy in rat models: A comparative study.

Authors:  Seda Duran G Ler; Mehmet Balbaba; Neriman Çolakoğlu; Özgör Bulmuş; Fatih Ulaş; Yesari Eröksüz
Journal:  Indian J Ophthalmol       Date:  2021-02       Impact factor: 1.848
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.